Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from RAW 264.7 macrophage

ABSTRACT: IFNg is a pro-inflammatory and pro-atherogenic cytokine that leads to macrophage activation. Adenosine has well-documented anti-inflammatory properties. We used microarrays to compare the global gene expression profile in mouse macrophages stimulated with IFNg alone and those cells treated with IFNg and adenosine. We determined that adenosine suppressed the expression of many IFNg-regulated pro-inflammatory cytokines, chemokines, and other pro-atherogenic genes. Keywords: treatment response RAW 264.7 cells were treated for 4 hours with either IFNg or IFNg plus adenosine. Following treatment, total RNA was extracted and treatment groups were pooled from 2 separate experiments for hybridization of Affymetrix microarrays.

ORGANISM(S): Mus musculus

SUBMITTER: Kimberly Barnholt

PROVIDER: E-GEOD-14612 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation.

Barnholt Kimberly E KE Kota Rama S RS Aung Hnin Hnin HH Rutledge John C JC

Journal of immunology (Baltimore, Md. : 1950) 20091021 10

Macrophages are activated by IFN-gamma, a proinflammatory and proatherogenic cytokine that mediates its downstream effects primarily through STAT1. IFN-gamma signaling induces phosphorylation of two STAT1 residues: Tyr(701) (Y701), which facilitates dimerization, nuclear translocation, and DNA binding; and Ser(727) (S727), which enables maximal STAT1 transcription activity. Immunosuppressive molecules such as adenosine in the cellular microenvironment can reduce macrophage inflammatory and ather ...[more]

PMID: 19846878

Similar Datasets

Expression data from RAW 264.7 macrophage

Project description:IFNg is a pro-inflammatory and pro-atherogenic cytokine that leads to macrophage activation. Adenosine has well-documented anti-inflammatory properties. We used microarrays to compare the global gene expression profile in mouse macrophages stimulated with IFNg alone and those cells treated with IFNg and adenosine. We determined that adenosine suppressed the expression of many IFNg-regulated pro-inflammatory cytokines, chemokines, and other pro-atherogenic genes. Keywords: treatment response

2009-12-31 | GSE14612 | GEO

LPS stimulation of Mouse (RAW 264.7) macrophages

Project description:Immunoresponsive gene 1 (IRG1) is one of the highest induced genes in macrophages under pro-inflammatory conditions and its function has been recently described: it codes for immune-responsive gene 1 protein/cis-aconitic acid decarboxylase (IRG1/CAD), an enzyme catalyzing the production of itaconic acid from cis-aconitic acid, a tricarboxylic acid (TCA) cycle intermediate. Itaconic acid possesses specific antimicrobial properties inhibiting isocitrate lyase, the first enzyme of the glyoxylate shunt, an anaplerotic pathway that bypasses the TCA cycle and enables bacteria to survive on limited carbon conditions. To elucidate the mechanisms underlying itaconic acid production through IRG1 induction in macrophages, we examined the transcriptional regulation of IRG1. Using a combination of literature information, transcription factor prediction models and genome-wide expression arrays, we inferred the regulatory network of IRG1 in mouse and human macrophages. 3 unstimulated (Control) and 3 LPS-stimulated RAW 264.7 macrophages

2016-02-25 | E-GEOD-76562 | biostudies-arrayexpress

Defining precision probes which differentiate between the activity of type I and type II interferons.

Project description:To define probes which differentiate between the activity of type I or type II IFN, a human submandibular gland (HSG) cell line was cultured for 48 hours in the absence or presence of IFNa or IFNg. Gene expression was assayed at 4, 12, 24 or 48 hours and was compared to gene expression in untreated cells at each time point to define genes which are induced by type I or type II IFN. HSG cells were cultured for 2 days in the absence or presence of IFNa [1000U/ml] or IFNg [50ng/ml], and total RNA was isolated at 4, 12, 24, and 48 hours of culture. Details are in the Analytical Methods section of the manuscript: John C. Hall, Livia Casciola-Rosen, Alan E. Berger, Efstathia Kapsogeorgou, Chris Cheadle, Athanasios G. Tzioufas, Alan N. Baer, Antony Rosen,Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases accepted for publication in PNAS (this GEO dataset will be released immediately upon electronic publication).

2012-10-08 | E-GEOD-41291 | biostudies-arrayexpress

NRROS negatively regulates ROS in phagocytes during host defense and autoimmunity

Project description:Production of reactive oxygen species (ROS) is one of the important antimicrobial mechanisms of phagocytic cells. Enhanced oxidative burst requires these cells to be primed with agents such as IFNg and LPS with a synergistic effect of these agents on the level of the burst. However, excessive ROS generation will lead to tissue damage and has been implicated in a variety of inflammatory and autoimmune disease. Therefore, this process needs to be tightly regulated. In order to understand the genes regulating this process, we will treat bone marrow derived macrophages with above mentioned priming agents and study the gene expression. We used microarrays to determine the changes in gene expression that occur in bone marrow derived macrophages after treatment with IFNg, LPS, or a combination of IFNg and LPS. Four condition experiment; Biological replicates: four replicates per condition

2014-03-31 | E-GEOD-53986 | biostudies-arrayexpress

LPS stimulation of Mouse (RAW 264.7) macrophages

2016-02-25 | GSE76562 | GEO

Global microRNA profiling of aTC1-6 and bTC1 before and after treatment with cytokines

Project description:The study sought to determine the global miRNA profiles of mouse pancreatic cell lines aTC1-6 and bTC1 at steady state and after treatment with a cocktail of pro-inflammatory cytokines (IL1b; IFNg and TNFa) for a time course of 24 and 48 hours. Inflammatory cocktail contains IL1b 50 IU/ml; IFNg 1000 IU/ml; TNFa 1000 IU/ml. MicroRNA expression profiles in both cell lines during the different experimental conditions were determined using TaqManM-BM-. Rodent miRNA A+B Cards Set v2.0 (TLDA, Life Technologies). MicroRNA profiles were measured in 3 independent biological replicates. qRT-PCR analysis of microRNAs of aTC1-6 treated with cytokines for 24 and 48 h and of their respective not-treated controls as well as of M-NM-2TC1 cells not treated with cytokines. 180 ng RNA of each sample was reverse transcribed through MegaplexM-bM-^DM-" RT Rodent Primer Pool sets A and B, and preamplified through MegaplexM-bM-^DM-" PreAmp Rodent Primer Pool sets (LifetechnologiesM-bM-^DM-"). Complementary DNA (cDNA) was amplified usingTaqManM-BM-. Rodent miRNA A+B Cards Set v2.0 (Life TechnologiesM-bM-^DM-") with TaqMan Universal PCR Master Mix on an ABI 7900HT Sequence Detection System.

2012-12-18 | E-GEOD-42970 | biostudies-arrayexpress

IFNg+ vs IFNg- Treg

Project description:Gene expression studies comparing IFNg+ Tregs versus IFNg- Tregs from human peripheral blood Ex vivo sorted Tregs (CD25highCD127neg) were stimulated for 4 hours and IFNg-secreting cells were detected by a IFNg-capture kit. The samples were resorted based on IFNg expression.

2016-07-01 | E-GEOD-71274 | biostudies-arrayexpress

Expresion data of Raw 264.7 cells treated with violacein

Project description:Violacein, an indole-derived purple-colored natural pigment isolated from Chromobacterium violaceum has shown multiple biological activities. In this study, we report that violacein activates murine macrophages through the up-regulation of TNF-α expression at non-cytotoxic concentrations (2 µmol/L). This was evaluated by measurement of TNF-α expression using real-time qRT-PCR. In addition, we obtained evidence of the molecular mechanism of activation by determining the mRNA expression pattern upon treatment with violacein. Interestingly, the mRNA expression pattern also allowed us to observe that incubation with violacein caused activation of pathways related with an immune and inflammatory response. Together, our data indicate that violacein activates the TLR8 receptor signaling pathway, and in consequence induces production of inflammatory cytokines such as TNF-α, CCL3 and CCL4 and of negative regulators of TLR signaling such as AP20, IRG1, IκBα and IκBε. Finally, we studied the interaction of TLR8 with violacein in silico, and obtained evidence that violacein could bind to TLR8 in a similar fashion to imidazoquinoline compounds. Therefore, our results indicate that violacein could be a candidate to be applied in immune therapy.

2019-09-25 | GSE82136 | GEO

Human IFNG+/- Treg and Tconv transcriptome

Project description:Microarray used to detail the global gene transcription underlying sorted IFNg+ and IFNg- Tregs (CD4+CD25+CD127lo) and Tconv (CD4+CD25-CD127+) for fresh (unexpanded) and 14 day expanded cells from human blood. Treg and Tconv were FACS isolated from five healthy subjects (median age of 26, range 22-30). Sorted cells were separated into two groups: the first group was stimulated for 4 hours with PMA/ionomycin and labeled with the IFNg cytokine capture kit (Miltenyi Biotech) followed by FACS isolation of IFNg- and IFNg+ populations. The second set was expanded to day 14 prior to reactivation and cytokine cell capture. For each IFNg sorted population, cells were pelleted and flash frozen before RNA isolation and processing.

2015-05-01 | E-GEOD-59786 | biostudies-arrayexpress

Exosomal miRNA signatures of RAW 264.7 cells

Project description:To investigate the exosomal miRNA changes under LPS treatment in RAW 264.7 cells, 2 μg/mL LPS were added into complete medium to incubate RAW 264.7 cells. And then The exosomes were isolated and tested the exosomal miRNAs change using microarray.

2023-04-30 | GSE149630 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data